Search Results - "Němeček, Radim"

Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options by Eid, Michal, Foukal, Jakub, Sochorová, Dana, Tuček, Štěpán, Starý, Karel, Kala, Zdeněk, Mayer, Jiří, Němeček, Radim, Trna, Jan, Kunovský, Lumír

“…Pheochromocytomas (PCCs) are rare neuroendocrine tumors derived from the chromaffin cells of the adrenal medulla. When these tumors have an extra‐adrenal…”
Get full text

Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer—A Critical Review and Practical Consideration by Burkoň, Petr, Trna, Jan, Slávik, Marek, Němeček, Radim, Kazda, Tomáš, Pospíšil, Petr, Dastych, Milan, Eid, Michal, Novotný, Ivo, Procházka, Tomáš, Vrzal, Miroslav

“…Pancreatic cancer is the third leading cause of cancer death in the developed world and is predicted to become the second by 2030. A cure may be achieved only…”
Get full text

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study by Hickish, Tamas, Dr, Andre, Thierry, MD, Wyrwicz, Lucjan, MD, Saunders, Mark, MBBS, Sarosiek, Tomasz, MD, Kocsis, Judit, MD, Nemecek, Radim, MD, Rogowski, Wojciech, MD, Lesniewski-Kmak, Krzysztof, MD, Petruzelka, Lubos, MD, Apte, Ron N, PhD, Mohanty, Prasant, MBBS, Stecher, Michael, MD, Simard, John, BS, de Gramont, Aimery, MD

“…Summary Background MABp1, an antibody that targets interleukin 1α, has been associated with antitumour activity and relief of debilitating symptoms in patients…”
Get full text

Current diagnostic and treatment options for pancreatic cancer in 2024 by Němeček, Radim, Karásek, Petr

“…Pancreatic ductal adenocarcinoma is a cancer disease with a very poor prognosis, which poses the third-leading cause of cancer-related deaths and whose…”
Get more information

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients by Lupini, Laura, Bassi, Cristian, Mlcochova, Jitka, Musa, Gentian, Russo, Marta, Vychytilova-Faltejskova, Petra, Svoboda, Marek, Sabbioni, Silvia, Nemecek, Radim, Slaby, Ondrej, Negrini, Massimo

“…The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or panitumumab are administered to colorectal cancer (CRC) patients…”
Get full text

The Pharmacoeconomic Analysis of Cetuximab and Panitumumab in the 1st Line Treatment of mCRC in Real Clinical Practice in the Czech Republic by Sehnalová, Irena, Říhová, Barbora, Němeček, Radim, Kintrová, Kateřina, Demlová, Regina

“…The anti-epidermal growth factor receptor (EGFR) drugs cetuximab and panitumumab are currently reimbursed when administered during the first and subsequent…”
Get more information

Current Possibilities for Predicting Responses to EGFR Blockade in Metastatic Colorectal Cancer by Němeček, R, Svoboda, M, Slabý, O

“…The combination of modern systemic chemotherapy and anti-EGFR monoclonal antibodies improves overall survival and quality of life for patients with metastatic…”
Get more information

MicroRNAs targeting EGFR signalling pathway in colorectal cancer by Mlcochova, Jitka, Faltejskova, Petra, Nemecek, Radim, Svoboda, Marek, Slaby, Ondrej

“…MicroRNAs (miRNAs) are short, 18–25-nucleotide long, non-coding single-stranded RNAs, which are capable to regulate gene expression on post-transcriptional…”
Get full text

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab by Mlcochova, Jitka, Faltejskova-Vychytilova, Petra, Ferracin, Manuela, Zagatti, Barbara, Radova, Lenka, Svoboda, Marek, Nemecek, Radim, John, Stanislav, Kiss, Igor, Vyzula, Rostislav, Negrini, Massimo, Slaby, Ondrej

“…The aim of our study was to investigate whether microRNAs (miRNAs) could serve as predictive biomarkers to anti-EGFR therapy (cetuximab, panitumumab) in…”
Get full text

First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study by Hegewisch-Becker, Susanna, Mendez, Guillermo, Chao, Joseph, Nemecek, Radim, Feeney, Kynan, Van Cutsem, Eric, Al-Batran, Salah-Eddin, Mansoor, Wasat, Maisey, Nicholas, Pazo Cid, Roberto, Burge, Matthew, Perez-Callejo, David, Hipkin, R William, Mukherjee, Sourav, Lei, Ming, Tang, Hao, Suryawanshi, Satyendra, Kelly, Ronan J, Tebbutt, Niall C

“…Open-label phase II study (RELATIVITY-060) to investigate the efficacy and safety of first-line nivolumab, a PD-1-blocking antibody, plus relatlimab, a…”
Get full text

THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS by SEHNALOVA, IRENA

Get full text

Deficient mismatch repair as a prognostic marker in stage II colon cancer patients by Gkekas, Ioannis, Novotny, Jan, Fabian, Pavel, Nemecek, Radim, Palmqvist, Richard, Strigård, Karin, Pecen, Ladislav, Svoboda, Tomas, Gurlich, Robert, Gunnarsson, Ulf

“…A number of reports have evaluated the relationship between deficient DNA mismatch repair (dMMR) and colorectal cancer prognosis. Unfortunately, the exact…”
Get full text

MABp1 to improve clinical outcomes of patients with symptomatic refractory metastatic colorectal cancer patients: Per-protocol population analysis of phase III study (PT026) by Wyrwicz, Lucjan, Saunders, Mark P., Andre, Thierry, Sarosiek, Tomasz, Nemecek, Radim, Rogowski, Wojciech, Leśniewski-Kmak, Krzysztof, Fisher, George A., Stecher, Michael, Mohanty, Prasant, Simard, John, Hickish, Tamas

“…Abstract only 3530 Background: Refractory metastatic colorectal cancer (mCRC) patients derive minimal benefit from further exposure to toxic agents. MABp1 is…”
Get full text

Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1) by Kurzrock, Razelle, Hickish, Tamas, Wyrwicz, Lucjan, André, Thierry, Sarosiek, Tomasz, Kocsis, Judit, Nemecek, Radim, Wu, Qian, Mohanty, Prasant, Stecher, Mike, Simard, John, Dinarello, Charles

Get full text

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy by Nemecek, Radim, Berkovcova, Jitka, Radova, Lenka, Kazda, Tomas, Mlcochova, Jitka, Vychytilova-Faltejskova, Petra, Slaby, Ondrej, Svoboda, Marek

“…Although several molecular markers predicting resistance to cetuximab- or panitumumab-based therapy of metastatic colorectal cancer were described, mutations…”
Get full text

Oncology in images: generalized Kaposi sarcoma by Svoboda, Marek, Grell, Peter, Nemecek, Radim, Sachlova, Milana, Slampa, Pavel

Get more information

Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute by Nēmecek, Radim, Kocáková, Ilona, Kocák, Ivo, Svoboda, Marek, Lakomý, Radek, Poprach, Alexandr, Vyskocil, Jirí, Vyzula, Rostislav

“…Combination of cetuximab and irinotecan is an efficacious second- (and further-)-line treatment-alternative in patients with EGFR-positive metastatic…”
Get more information